These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29756562)

  • 1. Perspectives and New Aspects of Metalloproteinases' Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine.
    Boguszewska-Czubara A; Budzynska B; Skalicka-Wozniak K; Kurzepa J
    Curr Med Chem; 2019; 26(18):3208-3224. PubMed ID: 29756562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous and synthetic MMP inhibitors in CNS physiopathology.
    Baranger K; Rivera S; Liechti FD; Grandgirard D; Bigas J; Seco J; Tarrago T; Leib SL; Khrestchatisky M
    Prog Brain Res; 2014; 214():313-51. PubMed ID: 25410364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system.
    Gardner J; Ghorpade A
    J Neurosci Res; 2003 Dec; 74(6):801-6. PubMed ID: 14648584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions.
    Mittal R; Patel AP; Debs LH; Nguyen D; Patel K; Grati M; Mittal J; Yan D; Chapagain P; Liu XZ
    J Cell Physiol; 2016 Dec; 231(12):2599-621. PubMed ID: 27187048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.
    Wang X; Khalil RA
    Adv Pharmacol; 2018; 81():241-330. PubMed ID: 29310800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and Biological Attributes of Matrix Metalloproteinases.
    Cui N; Hu M; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.
    Raeeszadeh-Sarmazdeh M; Do LD; Hritz BG
    Cells; 2020 May; 9(5):. PubMed ID: 32466129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus.
    Shukla V; Kumar Shakya A; Dhole TN; Misra UK
    Neuroimmunomodulation; 2012; 19(4):241-54. PubMed ID: 22441541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
    Chen Y; Peng W; Raffetto JD; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives.
    Behl T; Kaur G; Sehgal A; Bhardwaj S; Singh S; Buhas C; Judea-Pusta C; Uivarosan D; Munteanu MA; Bungau S
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in Matrix Metalloproteinases Inhibition.
    Laronha H; Carpinteiro I; Portugal J; Azul A; Polido M; Petrova KT; Salema-Oom M; Caldeira J
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32380782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain.
    Kuhad A; Singh P; Chopra K
    Expert Opin Ther Targets; 2015 Feb; 19(2):177-85. PubMed ID: 25243524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis.
    Pohl M; Sakurai H; Bush KT; Nigam SK
    Am J Physiol Renal Physiol; 2000 Nov; 279(5):F891-900. PubMed ID: 11053050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study.
    Mroczko B; Groblewska M; Barcikowska M
    J Alzheimers Dis; 2013; 37(2):273-83. PubMed ID: 23792694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).
    García-Onrubia L; Valentín-Bravo FJ; Coco-Martin RM; González-Sarmiento R; Pastor JC; Usategui-Martín R; Pastor-Idoate S
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.